ADHD co Alcobra to raise $16m on Nasdaq

The company will commence a Phase II/III trial on its ADHD drug after the IPO.

Attention deficit hyperactivity disorder (ADHD) treatment developer Alcobra Ltd. plans to issue 1,365,000 shares at $10-20 per share, according to the draft prospectus filed with the US Securities and Exchange Commission (SEC) today. The company plans to raise a gross $13.7-16.4 million at a company value of $92.5-110.9 million, after money. The company will be listed on Nasdaq under the ticker "ADHD".

Aegis Capital Corporation, which has a track record in floating new life sciences companies, will be the underwriter. Alcobra gave the investment bank an over-allotment option to buy up to 204,750 shares, which if exercised in full, will increase the gross proceeds by $2-2.5 million.

In the prospectus, Alcobra says that, in September 2011, it successfully completed a Phase II clinical trial of its drug, MG01CI, which included 120 patients, of its drug, and that it will commence a Phase II/III trial after the IPO. The IPO is intended to finance the heavy investment needed for this study. The company has raised $5.8 million since it was founded in 2008, but has only $97,000 in cash reserves.

Alcobra's founders, Dr. Dalia Megiddo and Udi Gilboa, will own 30.6% and 29.9% of the company, respectively, after the IPO. Based on the prospectus, the stakes will be worth up to $31 million and $30 million, respectively. Hadasit - the Technology Transfer Company of Hadassah Medical Organization owns 8.2%, and Alcobra CEO Dr. Yaron Daniely owns options exercisable for 1.7% of the company. Some of the options were granted for almost nothing compared with the planned IPO price.

Published by Globes [online], Israel business news - - on March 19, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018